Clinical trial may change the paradigm of care for patients with ALK-driven high-risk neuroblastoma

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Canada ,France ,United Kingdom ,Emily Henderson ,Yaelp Moss ,Kelly Goldsmith ,Baldrick Foundation ,Ronan Thompson Foundation ,Catherine Elizabeth Blair Memorial Foundation ,Emory University School Of Medicine ,Consortium Phase ,Cancer Center At Children Hospital Of Philadelphia ,Blood Disorders Center ,Children Neuroblastoma Cancer Foundation ,National Cancer Institute ,V Foundation For Cancer Research ,Wade Army ,Therapy Program ,Pfizer Inc ,International Society Of Paediatric Oncology European Neuroblastoma ,Alex Lemonade Stand Foundation ,Winship Cancer Institute Of Emory University ,Children Oncology Group ,Winship Cancer Institute ,Emory University ,New Approaches ,Neuroblastoma Therapy ,Nature Medicine ,Oncology Group ,International Society ,Paediatric Oncology European Neuroblastoma ,Senior Study Author ,Cancer Center ,Developmental Therapeutics Program ,Aflac Cancer ,Emory University School ,Industry Focus ,Solving Kids Cancer ,Cancer Research ,Lemonade Stand Foundation ,Neuroblastoma Cancer Foundation ,Kids Cancer ,Neuroblastoma ,Adolescents ,Dancer ,Fell ,Chemotherapy ,Children ,Clinical Trial ,Gene ,Enetic ,Healthcare ,Hospital ,Lung Cancer ,Lymphoma ,Medicine ,Ncology ,Ediatrics ,Research ,Translation ,Humor ,